Rubiayannone A

CAS No. 517918-25-1

Rubiayannone A( ——— )

Catalog No. M38310 CAS No. 517918-25-1

Rubiayannone A is an anthraquinone glycoside with an antiplatelet aggregation activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 1408 Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Rubiayannone A
  • Note
    Research use only, not for human use.
  • Brief Description
    Rubiayannone A is an anthraquinone glycoside with an antiplatelet aggregation activity.
  • Description
    Rubiayannone A is an anthraquinone glycoside with an antiplatelet aggregation activity.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    517918-25-1
  • Formula Weight
    550.469
  • Molecular Formula
    C25H26O14
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Meei-Jen Liou, et al. Constituents from Rubia Ustulata Diels and R. Yunnanensis Diels and Their Antiplatelet Aggregation Activity. Journal of the Chinese Chemical Society, 24 September 2013.
molnova catalog
related products
  • Picropodophyllin 4-O...

    Picropodophyllin-β-D-glucoside (compound 3) is a podophyllotoxin glucoside isolated from Chinese medicinal plants.

  • MK-0159

    MK-0159 is an orally available, highly potent CD38 inhibitor with myocardial injury protection for the study of cardiac ischemia and reperfusion injury.

  • WEHL-04

    WEHL-04 is an intermediate used to prepare (isoquinolinylsulfonyl)benzoic acids as inhibitors of type 5 71-β-hydroxysteroid dehydrogenase AKR1C3. It is also used in the synthesis of 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.